Ally Bridge Group’s Abivax ABVX Stock Holding History

Ally Bridge Group’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-33,712	Closed	-$3.82M	–	26
2026 Q1	$3.75M	Sell	33,712 -36,288	-52%	-$4.29M	3.03%	17
2025 Q4	$9.44M	Buy	+70,000	New	+$7.64M	9.83%	2

Other funds holding ABVX

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Jupiter Topco New York $245B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ally Bridge Group's ABVX Position: Q2 2026 in Review

Ally Bridge Group sold out of Abivax (ABVX) in Q2 2026, closing a stake of 33,712 shares — an estimated $3.82M sold.

Ally Bridge Group first reported a position in ABVX in Q4 2025 and held it in 2 quarters. The position peaked at $9.44M in Q4 2025. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

Ally Bridge Group reported no remaining Abivax position as of Q2 2026 after selling out during the quarter.
Ally Bridge Group sold 33,712 Abivax shares in Q2 2026, an estimated $3.82M.
Ally Bridge Group first reported a position in Abivax in Q4 2025 and held it in 2 quarters.
Ally Bridge Group's Abivax position peaked at $9.44M in Q4 2025.
302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Ally Bridge Group's 13F filing for Q2 2026, filed 14 Aug 2026.